• Users Online: 26
  • Print this page
  • Email this page
Year : 2021  |  Volume : 33  |  Issue : 1  |  Page : 6-11

Serum osteopontin as a blood biomarker in relapsing–remitting multiple sclerosis Egyptian patients

1 Department of Clinical Pathology, Om El Masreen Hospital, Cairo, Egypt
2 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3 Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Mohamed A Abdel Hafeez
MD, Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo 11591
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejolm.ejolm_3_22

Rights and Permissions

Background Osteopontin (OPN) is a widely expressed acidic glycoprotein, and is considered as an interesting biomarker because of its role in the pathophysiology of several inflammatory, degenerative, autoimmune, and oncologic diseases. This study aimed to evaluate serum OPN as a blood biomarker in relapsing–remitting multiple-sclerosis (RRMS) Egyptian patients and correlate it with disease activity. Patients and methods This case–control study recruited consecutively 90 patients divided into two groups: group I includes 30 age-matched and sex-matched healthy individuals as control group, and group II includes 60 RRMS patients, which in turn was subdivided into two subgroups: group IIa including 30 patients in remission and group IIb including 30 patients in relapse before receiving methyl prednisolone. All patients were subjected to full history taking, neurological examination using Expanded Disability Status Scale assessment, and laboratory investigations, including complete blood count, aspartate aminotransferase, alanine aminotransferase, and OPN-level measurement. Results A highly significant difference between group I and group II as regards OPN level (P < 0.001). Receiver operating characteristic curve for OPN level between group I and group II showed that the cutoff level of more than 8 can discriminate between both groups with 88.33% sensitivity and 100% specificity. There was a significant correlation between OPN level and AST (P < 0.05). Conclusion OPN can be used as an inflammatory biomarker to differentiate between RRMS patients and healthy individuals but cannot discriminate between remission and relapse in MS patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded20    
    Comments [Add]    

Recommend this journal